Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 3
2002 1
2003 5
2004 3
2005 5
2006 10
2007 8
2008 5
2009 17
2010 18
2011 14
2012 30
2013 17
2014 32
2015 33
2016 36
2017 49
2018 51
2019 74
2020 81
2021 98
2022 76
2023 82
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

695 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ppar g cancer (418 results)?
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J, Bouras E, Constantinescu A, Burrows K, Bull CJ, Vincent EE, Martin RM, Dimopoulou O, Lewis SJ, Moreno V, Vujkovic M, Chang KM, Voight BF, Tsao PS, Gunter MJ, Hampe J, Pellatt AJ, Pharoah PDP, Schoen RE, Gallinger S, Jenkins MA, Pai RK; PRACTICAL consortium; VA Million Veteran Program; Gill D, Tsilidis KK. Yarmolinsky J, et al. Diabetologia. 2023 Aug;66(8):1481-1500. doi: 10.1007/s00125-023-05925-4. Epub 2023 May 12. Diabetologia. 2023. PMID: 37171501 Free PMC article.
In co-localisation analysis, however, there was little evidence of shared causal variants for type 2 diabetes liability and cancer endpoints in the PPARG locus, although these analyses were likely underpowered. There was little evidence to support associations betwe …
In co-localisation analysis, however, there was little evidence of shared causal variants for type 2 diabetes liability and cancer en …
Pparg signaling controls bladder cancer subtype and immune exclusion.
Tate T, Xiang T, Wobker SE, Zhou M, Chen X, Kim H, Batourina E, Lin CS, Kim WY, Lu C, Mckiernan JM, Mendelsohn CL. Tate T, et al. Nat Commun. 2021 Oct 25;12(1):6160. doi: 10.1038/s41467-021-26421-6. Nat Commun. 2021. PMID: 34697317 Free PMC article.
Pparg, a nuclear receptor, is downregulated in basal subtype bladder cancers that tend to be muscle invasive and amplified in luminal subtype bladder cancers that tend to be non-muscle invasive. ...We find that expression of an activated form of Pparg …
Pparg, a nuclear receptor, is downregulated in basal subtype bladder cancers that tend to be muscle invasive and amplified in …
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. Chu CE, et al. Clin Cancer Res. 2021 Sep 15;27(18):5123-5130. doi: 10.1158/1078-0432.CCR-20-4175. Epub 2021 Jun 9. Clin Cancer Res. 2021. PMID: 34108177 Free PMC article.
The outcome of the transcriptomic analysis was relative NECTIN4 expression in the consensus molecular subtypes of bladder cancer. Expression of NECTIN4 was validated in bladder cancer cell lines. ...RESULTS: NECTIN4 expression is heterogenous across molecular subtyp …
The outcome of the transcriptomic analysis was relative NECTIN4 expression in the consensus molecular subtypes of bladder cancer. Exp …
The ménage à trois of autophagy, lipid droplets and liver disease.
Filali-Mouncef Y, Hunter C, Roccio F, Zagkou S, Dupont N, Primard C, Proikas-Cezanne T, Reggiori F. Filali-Mouncef Y, et al. Autophagy. 2022 Jan;18(1):50-72. doi: 10.1080/15548627.2021.1895658. Epub 2021 Apr 2. Autophagy. 2022. PMID: 33794741 Free PMC article. Review.
Particular attention is paid to the role of macroautophagy and macrolipophagy in relation to the parenchymal and non-parenchymal cells of the liver in NASH, as this disease has been associated with inappropriate lipophagy in various cell types of the liver.Abbreviations: ACAT: ac …
Particular attention is paid to the role of macroautophagy and macrolipophagy in relation to the parenchymal and non-parenchymal cells of th …
Small cell lung cancer with SYN2::PPARG fusion.
Ghigna MR, Cotteret S, Arbab A, Bani MA, Scoazec JY. Ghigna MR, et al. Pathol Res Pract. 2023 Nov;251:154904. doi: 10.1016/j.prp.2023.154904. Epub 2023 Oct 28. Pathol Res Pract. 2023. PMID: 38238071
INTRODUCTION: Small cell lung cancer (SCLC) accounts for 15% of lung cancers worldwide. It is an aggressive tumor that is typically diagnosed at an advanced stage. ...METHODS: We conducted a retrospective examination of molecular findings in lung cancer patie …
INTRODUCTION: Small cell lung cancer (SCLC) accounts for 15% of lung cancers worldwide. It is an aggressive tumor that is typi …
PPARG: A Promising Therapeutic Target in Breast Cancer and Regulation by Natural Drugs.
Li DH, Liu XK, Tian XT, Liu F, Yao XJ, Dong JF. Li DH, et al. PPAR Res. 2023 Jun 8;2023:4481354. doi: 10.1155/2023/4481354. eCollection 2023. PPAR Res. 2023. PMID: 37334066 Free PMC article.
Breast cancer (BC) is the most common type of cancer among females. Peroxisome proliferator-activated receptor gamma (PPARG) can regulate the production of adipocyte-related genes and has anti-inflammatory and anti-tumor effects. ...Using different bioinforma …
Breast cancer (BC) is the most common type of cancer among females. Peroxisome proliferator-activated receptor gamma (PPARG …
A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer.
Tortora D, Roberts ME, Kumar G, Kotapalli SS, Ritch E, Scurll JM, McConeghy B, Sinha S, Wyatt AW, Black PC, Daugaard M. Tortora D, et al. iScience. 2023 Mar 30;26(5):106525. doi: 10.1016/j.isci.2023.106525. eCollection 2023 May 19. iScience. 2023. PMID: 37250326 Free PMC article.
Here, we developed an endogenous PPARG reporter system in luminal bladder cancer cells and performed genome-wide CRISPR knockout screening to identify bona fide regulators of PPARG gene expression. Functional validation of the dataset confirmed GATA3, SPT6, a …
Here, we developed an endogenous PPARG reporter system in luminal bladder cancer cells and performed genome-wide CRISPR knocko …
Blocking PPARgamma interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression.
Yang PB, Hou PP, Liu FY, Hong WB, Chen HZ, Sun XY, Li P, Zhang Y, Ju CY, Luo LJ, Wu SF, Zhou JX, Wang ZJ, He JP, Li L, Zhao TJ, Deng X, Lin T, Wu Q. Yang PB, et al. Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27412-27422. doi: 10.1073/pnas.2002997117. Epub 2020 Oct 21. Proc Natl Acad Sci U S A. 2020. PMID: 33087562 Free PMC article.
Cocrystallographic and functional analysis revealed that Csn-B, a Nur77-targeting compound, promoted the formation of Nur77 homodimer to prevent PPARgamma binding by steric hindrance, thereby strengthening the Nur77's inhibitory role in breast cancer. Therefore, our study …
Cocrystallographic and functional analysis revealed that Csn-B, a Nur77-targeting compound, promoted the formation of Nur77 homodimer to pre …
PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis.
Ding H, Chen Y, Qiu H, Liu C, Wang Y, Kang M, Tang W. Ding H, et al. Oncotarget. 2017 Sep 15;8(60):102277-102290. doi: 10.18632/oncotarget.20925. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254243 Free PMC article.
In a subgroup analysis by cancer type, PPARG c.1347C>T polymorphism was associated with risk of esophageal cancer and glioblastoma. ...In conclusion, the findings indicate PPARG c.1347C>T polymorphism may increase the susceptibility of cancer …
In a subgroup analysis by cancer type, PPARG c.1347C>T polymorphism was associated with risk of esophageal cancer an …
Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer.
Goldstein JT, Berger AC, Shih J, Duke FF, Furst L, Kwiatkowski DJ, Cherniack AD, Meyerson M, Strathdee CA. Goldstein JT, et al. Cancer Res. 2017 Dec 15;77(24):6987-6998. doi: 10.1158/0008-5472.CAN-17-1701. Epub 2017 Sep 18. Cancer Res. 2017. PMID: 28923856 Free PMC article.
Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated bladder cancer cells. Our results offer a preclinical proof of concept for PPARG as a candidate therapeutic target in bladder …
Reducing PPARG activity, whether by pharmacologic inhibition or genetic ablation, inhibited proliferation of PPARG-activated b …
695 results